Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/24H stock hub

FRA/24H has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/24His not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

267.3M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/24HFRA/24H

—

Loading chart…

In the news

Latest news · FRA/24H

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-56.5

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/24H market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

150

Groups with data

Currency

SEK

Showing 150 of 150 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Sweden
Country code	DE
Employees	122
Employees Change	-2%
Employees Change Percent	-1.48
Enterprise value	EUR 310.3M
Exchange	Frankfurt Stock Exchange
Financial currency	SEK
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 267.3M
Price	EUR 2.51
Price currency	EUR
Rev Per Employee	142,292.98x
Sic	2836
Symbol	fra/24H
Website	https://www.hansabiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-23.57%
EV Earnings	-4.92x
EV/Sales	17.68x
P/B ratio	-10.66x
P/S ratio	15.4x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-299.37%
EBITDA Margin	-298.07%
Gross margin	59.67%
Gross Profit	EUR 10.4M
Gross Profit Growth	18.68%
Gross Profit Growth Q	-54.64%
Gross Profit Growth3 Y	0.63%
Gross Profit Growth5 Y	57.03%
Net Income	EUR -63M
Pretax Margin	-361.81%
Profit Per Employee	EUR -516,610
ROA	-38.17
Roa5y	-33.49
ROCE	-60.45
ROIC	-56.51

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	7.63%
Cagr3y	-18.66%
Cagr5y	-29.6%
Revenue Growth	4.85x
Revenue Growth Q	-47.9x
Revenue Growth3 Y	8.67x
Revenue Growth5 Y	68.05x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.2
Assets	EUR 105.9M
Cash	EUR 61.6M
Current Assets	EUR 73.1M
Current Liabilities	EUR 20.1M
Debt	EUR 104.1M
Equity	EUR -25.1M
Interest Coverage	-2.55
Liabilities	EUR 131M
Long Term Assets	EUR 32.8M
Long Term Liabilities	EUR 110.9M
Net Cash	EUR -42.5M
Net Cash By Market Cap	EUR -15.88
Tangible Book Value	EUR -46.4M
Tangible Book Value Per Share	EUR -0.46

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.63
Inventory Turnover	17.2
Net Working Capital	EUR -8.6M
Quick ratio	3.6
Working Capital	EUR 52.4M
Working Capital Turnover	EUR 0.04

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-34.63%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	7.63%
200-day SMA	2.86
3Y total return	-46.19%
50-day SMA	2.66
50-day SMA vs 200-day SMA	50under200
5Y total return	-82.71%
All Time High	32.88
All Time High Change	-92.36%
All Time High Date	2018-10-09
All Time Low	1.71
All Time Low Change	46.56%
All Time Low Date	2023-10-16
ATR	0.07
Ch YTD	-26.12
High	2.51
High52	3.8
High52 Date	2026-02-13
High52ch	-33.89%
Low	2.51
Low52	2.02
Low52 Date	2025-06-03
Low52ch	24.36%
Ma50ch	-5.53%
Price vs 200-day SMA	-12.23%
RSI	47.79
RSI Monthly	43.98
RSI Weekly	44.84
Sharpe ratio	0.47x
Sortino ratio	0.78
Total Return	-34.63%
Tr YTD	-26.12
Tr1m	-13.74%
Tr1w	2.45%
Tr3m	-25.01%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -52M
Operating margin	-299.4

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	74,057,974%
Net Borrowing	10,687,834.2
Shares Insiders	6.12%
Shares Institutions	21.68%
Shares Qo Q	0%
Shares Yo Y	34.63%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	0x
Bv Per Share	-0.25
Ch1m	-13.74
Ch1w	2.45
Ch1y	7.63
Ch3m	-25.01
Ch3y	-46.19
Ch5y	-82.71
Ch6m	2.2
Change	1.21%
Change From Open	0
Close	2.48
Days Gap	1.21
Depreciation Amortization	229,157.8
Earnings Date	2026-07-16
EBIT	EUR -52M
EBITDA	EUR -51.7M
EPS	EUR -0.7
F Score	3
Financing CF	89,480,422
Fiscal Year End	December
Founded	2,007
Income Tax	EUR 217,263
Is Primary Listing	0
Last Earnings Date	2026-03-26
Last Report Date	2026-03-31
Ma150	2.91
Ma150ch	-13.56%
Ma20	2.5
Ma20ch	0.44%
Net CF	38,846,943
Next Earnings Date	2026-07-16
Open	2.51
Ppne	981,316.1
Price Date	2026-05-08
Relative Volume	2,000x
Revenue	17,359,743x
SBC By Revenue	18.26x
Share Based Comp	3,170,277
Tax By Revenue	1.25x
Tr6m	2.2%

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/24H pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/24H stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/24H?

Insider, institutional, and short-interest positioning.

Institutional ownership

+21.7%

Share of float held by funds and institutions

Insider ownership

+6.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+34.6%

Negative means the company is buying back shares.

Technical

FRA/24H momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

47.8

Neutral momentum band

Price vs 200-day MA

-12.2%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.47

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/24H

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/24H stock rating?

fra/24H is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/24H analysis?

The full report lives at /stocks/fra/24H/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/24H?

The latest report frames fra/24H around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/24H page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.